Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
Withdrawn before enrolling · Phase 2
Conditions studied: Neuroblastoma
In brief
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and children with relapsed NBL have an overall 3 year survival rate of \< 10%. Hematopoietic Stem Cell Transplant from a different donor (allogeneic), is a form of adoptive cellular therapy , such that infused donor cells find host tumors as foreign and fight them. After transplant, the donor immune cells (i.e. T cells, NK cells) mediate Graft versus Tumor (GVT) effect and may stop tumor from recurring. Also,reduced intensity transplants lead to minimal toxicity and less risk of mortality in heavily pre-treated NBL patients. PURPOSE: This phase II trial is studying how well giving a reduced intensity(using Fludarabine, Busulfan and antithymocyte globulin)preparative regimen followed by donor stem cell transplant works in treating young patients with high-risk neuroblastoma that has relapsed or not responded to treatment.
Key facts
- Study ID
- NCT00874315
- Run by
- Nationwide Children's Hospital
- People needed
- 0
- Starts
- 2008-09-01
- Expected to finish
- 2012-06-01
- Last updated by the study team
- 2015-10-16
Who can join
Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Memorial Hospital — Chicago, Illinois, United States
- Morgan Stanley Children's Hospital of NY — New York, New York, United States
- Nationwide Children's Hospital — Columbus, Ohio, United States
- Children's Hopsital of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.